ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exploring Cognitive Dysfunction in Rheumatology

Ruth Jessen Hickman, MD  |  November 17, 2025

Dr. Katz also pointed to some of the factors associated with cognitive dysfunction in people with RA, some of which are also seen in the general populations. These include certain medications, such as oral glucocorticoids. Comorbid conditions, such as cardiovascular disease and cerebrovascular disease, increase risk. Depression is an especially important factor to treat and address, as it may sometimes partly manifest with impaired cognitive function. Lifestyle issues, especially poor sleep and low levels of physical activity, also seem to play a role.

Scleroderma

More than half of people with scleroderma may experience bothersome symptoms affecting their memory and executive function, with at least one study reporting this number at 87%. In addition to factors already discussed, patients with scleroderma may have additional disease-related factors related to cognitive dysfunction, such as poorer nutrition and decreased oxygen intake.10-13

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Chen emphasized the importance of providing patients with compensatory strategies to help them better navigate their cognitive challenges. For example, establishing routines, setting reminders (e.g., on a phone) and making to-do lists can all help patients better manage their lives.

Relatedly, Dr. Chen discussed her work with the Brain Boost Program, designed as an eight-week online educational group-based program as part of a pilot randomized, controlled trial. Through the program, participants play online brain games to sharpen their mental acuity and also learn cognitive strategies and lifestyle modifications to help them better manage their situation. Although results of the trial are not yet available, many participants have shared enthusiastic responses.14

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Management Considerations

Sometimes, just asking about potential cognitive symptoms is enough to begin a helpful discussion. Dr. Whibley also recommended the National Institutes of Health (NIH) Toolbox Cognition Battery as a resource to provide brief initial screening and assessment, although this shouldn’t replace more thorough testing when needed. Dr. Chen also recommended the cognitive function measure on PROMIS (Patient-Reported Outcomes Measurement Information System), which assesses an individual’s perceived cognitive abilities.

Dr. Katz noted that disease control is an important element of addressing cognitive concerns, as patients with higher inflammation and pain are likely to have greater problems with cognitive functioning. She also recommended minimizing steroid use, controlling comorbidities, especially cardiovascular disease, and treating such mental health issues as depression. Encouraging exercise and screening for sleep problems are also critical.

Dr. Chen also suggested involving occupational and/or physical therapists who can help provide specific cognitive aids and strategies, help patients manage their energy and tailor exercise programs to patients’ specific abilities. If available, cognitive rehabilitation programs can also be beneficial.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ACR ConvergenceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2025ACR Convergence 2025 - RAcognitive dysfunctionFibromyalgiaRheumatoid arthritisScleroderma

Related Articles

    Revising Fibromyalgia: One Year Later

    July 12, 2011

    The 2010 ACR fibromyalgia criteria capture the broader clinical picture and help ensure more appropriate diagnosis and management by primary care

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Lupus in the Child’s Mind

    March 1, 2009

    Unique neuropsychiatric problems require a unique approach

    Pinpoint Cognitive Dysfunction in Patients with Lupus

    April 6, 2012

    More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. “Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences